Home » Stocks » CAPR

Capricor Therapeutics, Inc. (CAPR)

Stock Price: $4.03 USD 0.00 (0.00%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $4.06 +0.03 (0.74%) Nov 25, 7:59 PM

Stock Price Chart

Key Info

Market Cap 82.40M
Revenue (ttm) 474,520
Net Income (ttm) -10.95M
Shares Out 20.45M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $4.03
Previous Close $4.03
Change ($) 0.00
Change (%) 0.00%
Day's Open 4.00
Day's Range 3.87 - 4.13
Day's Volume 497,313
52-Week Range 0.88 - 12.32

More Stats

Market Cap 82.40M
Enterprise Value 47.42M
Earnings Date (est) Mar 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 20.45M
Float 19.91M
EPS (basic) -1.03
EPS (diluted) -0.95
FCF / Share -0.42
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.19M
Short Ratio 2.48
Short % of Float 5.98%
Beta 7.33
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 173.66
PB Ratio 2.89
Revenue 474,520
Operating Income -10.99M
Net Income -10.95M
Free Cash Flow -8.26M
Net Cash 34.98M
Net Cash / Share 1.71
Gross Margin -871.78%
Operating Margin -2,316.61%
Profit Margin -2,307.30%
FCF Margin -1,740.06%
ROA -31.16%
ROE -64.44%
ROIC -1,030.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$12.00*
Low
12.0
Current: $4.03
High
12.0
Target: 12.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1.011.672.674.005.524.790.501.901.35-
Revenue Growth-39.87%-37.32%-33.32%-27.53%15.27%851.19%-73.5%40.18%--
Gross Profit1.011.672.674.005.524.790.501.901.35-
Operating Income-7.73-15.33-12.86-16.98-12.61-6.02-6.90-2.10-4.90-6.29
Net Income-7.64-15.192.43-18.81-12.86-6.22-8.89-2.07-4.88-6.03
Shares Outstanding3.712.942.321.861.591.171.050.990.070.06
Earnings Per Share-2.06-5.170.90-10.10-8.10-5.30-8.50-2.10-65.00-95.00
Operating Cash Flow-6.82-13.86-14.23-14.45-10.820.96-6.14-2.06-4.65-4.32
Capital Expenditures--0.32-0.03-0.19-0.15-0.19-0.06-0.01--
Free Cash Flow-6.82-14.18-14.26-14.65-10.970.77-6.20-2.08-4.65-4.32
Cash & Equivalents9.897.5414.8717.5413.5711.013.464.381.093.38
Total Debt---13.919.169.163.96---
Net Cash / Debt9.897.5414.873.644.411.86-0.504.381.093.38
Assets11.119.2516.2718.7516.0713.635.545.421.373.67
Liabilities4.274.635.0522.7517.1019.886.070.530.541.07
Book Value6.844.6211.23-4.00-1.03-6.25-0.534.890.832.60
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Capricor Therapeutics, Inc.
Country United States
Employees 16
CEO Linda Marbán

Stock Information

Ticker Symbol CAPR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CAPR

Description

Capricor Therapeutics, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.